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There are as many mutated or gone awry
potential biological targets in hyper-
proliferative cells as there are steps in the
biological processes of cellular respiration,
metabolism, apoptosis and glycolysis. This
heterogeneity is the single greatest obstacle to
cancer therapy. Even the Warburg effect, i.e.
that of hypoxic cancer cells primarily resorting
to glycolysis to fulfill their energy needs due to
impaired oxidative phosphorylation, does not
seem to be true of many cancers. However, a
commonality between many cancers is that they
have increased rates of glucose uptake that is, in
turn, achieved by overexpression of cell
membrane localized uniporters called glucose
transporters or GLUT. A 'near universal'
approach to kill cancer cells lies in depriving
them of their metabolic fuel, i.e. the preferential
blockage of GLUT on malignant cells while
sparing GLUT on normal cells. How might this
be achieved?
As a first approximation, if glucose molecules
could be conjugated to polyethylene glycol
(PEG-Glu) at an end-to-end span distance
lesser than the mean distance between two
glucose transporters in normal cells, it could
theoretically be possible to preferentially disable
GLUT receptors on malignant cells on an
equimolar excipient basis. An internet search
obtained one hit that espoused substantially the
same idea in the US patent 20,110,243,851 A1
entitled “Glucose-PEG conjugates for reducing
glucose transport into  a cell” (1). While proof
of concept was demonstrated in this patent
application, the inventors did not suggest any
method for sparing GLUT on normal cells
while only blocking those on malignant hyper-
proliferative cells. They also envisaged the use
of this molecule as a drug rather than as an
excipient.
Overexpression of GLUT transporters in the
cell membrane of malignant cells must
necessarily decrease the mean distance between
two transporter-receptors. If the end-to-end
distance between the glucose conjugated sites
of the PEG molecule approximates this
decreased distance, then the glucose moieties in
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Figure 1 Proposed PEG-Glu Structure
preferentially bind to malignant cells.
Differential glucose deprivation of malignant
cells is expected to cause necrosis or apoptosis
of those cells depending on the functional state
of the mitochondria.
Using the following general approximations:
Weight of one cell: 1 ng
Expression of GLUT transporters in a normally
respiring cell: 15 [pmol/mg]
Diameter of an average cell: 50 µm.
Mean molecular weight of GLUT isoforms: 45 kDa
Mean cross-sectional pore area of trans-membrane
GLUT transporter: 5 pm
and, assuming that the GLUT transporters are
evenly distributed across the cell membrane, the
calculated  surface area of a cell works out to be
7850 X 106 nm2 and there are 1.15 transporters
per 1000 nm2 cell surface. Therefore, the mean
distance between the GLUT transporters on
the cell membrane is 31 nm. Since the carbon-
carbon bond length is 0.154 nm, there would
need to be 200 carbon atoms between the two
glucose residues conjugated to the PEG
molecule. A 2.4 kDa PEG conjugated at both
ends with glucose molecules should therefore
bind to the GLUT transporters on non-
transformed cells. It can be assumed that a
PEG molecule with a molecular weight
significantly lesser than 2 kDa will only be able
to block one GLUT receptor per molecule. 
Assuming a two-fold, or greater, expression of
GLUT transporters on transformed or hyper-
proliferative cells, the mean GLUT distance will
be halved to 15 nm or less. Since the Michaelis
constant for GLUT-1 transporters for glucose
is 16.9 to 26.2 mM, and the GLUT-1 isoform is
the one reported to be the most over expressed
on malignant cell lines, it is reasonable to
conclude that the binding enthalpy of glucose
and GLUT is not significantly greater than the
hydrogen bonding enthalpy between the PEG-
glucose conjugate and aqueous blood such that
equimolar concentrations of the conjugate will
accumulate on both malignant cells over-
expressing the GLUT transporter as well as on
non-malignant cells. Therefore, as a first
approximation, it can be reasonably concluded
that a PEG with a molecular weight of 1000 Da
or less, that is conjugated at both ends (as well
as on the intermediate carbons) with glucose
moieties will disable proportionally more
GLUT receptors per mole on malignant cells
than on normal cells at non-saturated ligand
concentrations. Note that the model assumes
rigid C-C bonds incapable of rotation about the
bond axis and that stearic effects are neglected.
No doubt, much better approximations will be
possible with molecular docking and binding
software simulations although the driving
principle of the hypothesis is expected to
remain unchanged.
Since the glucose is conjugated to the PEG
through its aldehyde containing C-1 carbon, it
is no longer a reducing sugar and cannot
degrade the API through reactions
characteristic of such sugars (see Figure 1 for a
proposed structure of the molecule). The
molecule is expected to behave as a non-
crystalline entity when frozen thereby affording
protection to protein APIs' during
lyophilization via the water-replacement
hypothesis. Aqueous solutions of PEG-Glu are
expected to exhibit a lower dielectric constant
than water, thereby allowing a greater amount
of API dissolution with a lesser amount of
surfactants. The molecule thus appears to be no
less inferior than existing excipients in its





solubilizing and stabilizing properties and could
thus be envisaged as an excipient in lyophilized
(small molecule or protein) formulations or as
an infusion medium in leu of D5W or saline for
intravenous infusion or bolus administration of
antineoplastic drugs.
The current state of excipient innovation is
essentially limited by what combinations and
permutations of molecules can be siphoned off
from the food industry. While the example of
PEG-Glu structurally fits into that category,
this molecule as described in this editorial has
been intentionally designed, rather than
accidentally found, to be in vivo enabling. There
are many excipients that have been
serendipitously discovered to possess bioactive
target engagement capability but were not
explicitly so designed for that purpose. As just
one example, the broad range of surfactants
used in pharmaceutical dosage forms have been
found to possess varying magnitudes of P-
glycoprotein modulatory function that is now
recognized as a primary effector in preventing
multi drug resistance (MDR). Therefore,
evidence of pharmacological in-vivo target
engagement (whether deliberately built into the
structure or found after years of use), in and of
itself, is not sufficient to deny an 'excipient'
designation to molecules so long as they
perform their usual (obligatory) functions of
filler, binder, solubilizer etc. An API,
tranexamic acid, has been used as an excipient
in Reteplase® as a solubilizing agent for the
non-glycosylated protein molecule. Precedence
notwithstanding, many pharmaceutical
excipients and even food ingredients possess de-
novo pharmacological activity (and hence, by
definition, modulate cellular receptors and/or
targets), as indeed, does glucose itself via its
GLUT pharmacological target.
Although polyethylene glycols are not absorbed
from the gut, could decreasing their molecular
weight by orders of magnitude (< 5 carbon
backbone) enable oral bioavailability while
preserving their GLUT blocking functionality?
When ligated with sucrose (PEG-Suc) could
they be absorbed from the gut? In another
admittedly speculative twist to this intriguing
story; would it then make sense from a public
health viewpoint to add such low molecular
weight PEG-Suc to sugar for mass
consumption? In vivo enzymatic hydrolysis of
sucrose to glucose would leave PEG-Glu that
would function as a proliferative cell inhibitor.
Could PEG-Gly be added to isotonic D5W or
saline or, even be substituted for the latter,
especially for infusing cancer patients?
The pharmaceutical industry should examine
unfulfilled in vivo needs, such as that described
above, that could be met by excipients, either
alone or in synergistic combination with active
ingredients. This will enable innovative a’ priori
design of new excipient molecules to provide
value added propositions to the pharmaceutical
industry. Explicit recognition by regulatory
agencies that in vivo receptor target engagement
is not necessarily alien to excipient property,
design or function  will go a long way toward
expanding excipient innovation and scope. The
intent of such a paradigm is not to somehow
del iberately endow excipients  with
pharmacological properties, that most
(beknownst or unbeknownst) already possess ,
but to take these cogent issues of excipient
definition, properties and function into account
when formulating regulatory policy for
pharmaceutical excipients.
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